Immunotherapy for Prostate Carcinoma

Publication Date: December 20, 2016

Key Points

Key Points

Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer death among men in the United States.

Early detection combined with an indolent disease course likely account for the high 5-year survival, approaching 100% for newly diagnosed localized (stage I and II) or regional (stage III) disease.

However, approximately one-third of early stage patients will develop recurrence, often with metastatic (stage IV) disease. For patients with metastatic disease, 5-year survival rates decrease to 28%.

Androgen deprivation therapy (ADT) is the mainstay of initial therapy for metastatic disease, but resistance eventually develops in nearly all men.

In the past 6 years, a number of therapies have been approved for metastatic castration-resistant prostate cancer (mCRPC), including androgen signaling inhibitors (enzalutamide, abiraterone acetate), cytotoxic chemotherapy (cabazitaxel), a radiopharmaceutical (radium-223), and immunotherapy (sipuleucel-T, the first and currently only immunotherapeutic agent approved for mCRPC).

Immunotherapy for Prostate Cancer

...erapy for Prostate Cancer...

Immunotherapy for non-mCRPC

...notherapy for non-mCRPC...

...on recent data and accumulated experience with im...


Selecting Patients for Immunotherapy

...ecting Patients for Immunoth...

...for sipuleucel-T in the management of asymp...


Corticosteroid Therapy, Chemotherapy, and Secondary Hormonal Agents

...steroid Therapy, Chemotherapy, and Secondary Hor...

...icosteroid doses equivalent to ≤10mg/d...


...s who have been treated with abiraterone/cor...


Sequence of Agents

...tsSipuleucel-T first. (90%) An androgen recep...

Sipuleucel-T

...puleucel-T...

...es for use of sipuleucel-T as provided in the...


...dard PSA and radiologic monitoring should...


...n new baseline PSA and imaging immed...


Therapy Subsequent to Sipuleucel-T

...herapy Subsequent to Si...

...DA has drafted guidance for industry concerning...


...an event/progression before beginning a sub...